Current clinical perspectives on antiarrhythmic drug therapy

Area of Science:

• Cardiology
• Pharmacology
• Electrophysiology

Background:

• Arrhythmia evaluation and treatment are evolving due to new diagnostic methods, antiarrhythmic agents, and risk concepts.
• Ventricular arrhythmias, categorized by risk (benign, potentially lethal, lethal), necessitate tailored therapeutic strategies.
• Advanced heart disease, such as myocardial infarction, significantly increases risk in patients with complex arrhythmias.

Purpose of the Study:

• To review the changing landscape of arrhythmia evaluation and therapy.
• To discuss the classification and limitations of current antiarrhythmic drugs.
• To highlight emerging pharmacological and non-pharmacological treatment modalities.

Main Methods:

• Review of current literature on arrhythmia diagnosis and treatment.
• Classification of antiarrhythmic drugs based on electrophysiological and pharmacological effects.
• Discussion of novel pharmacological agents and non-pharmacological interventions.

Main Results:

• Three risk categories for ventricular arrhythmias are defined: benign, potentially lethal, and lethal.
• Potentially lethal arrhythmias in advanced heart disease indicate a two- to fourfold increased risk.
• New antiarrhythmic agents (tocainide, mexiletine, flecainide, amiodarone) and non-pharmacological therapies (ablation, pacemakers, defibrillators) are expanding treatment options.

Conclusions:

• The approach to arrhythmia management is rapidly advancing with new diagnostic and therapeutic options.
• While current antiarrhythmic drugs have limitations, new agents offer expanded therapeutic scope.
• Novel non-pharmacological therapies and advanced devices promise more specific and successful arrhythmia management.